On March 30, 2011 Dr. Reddy’s Laboratories (NYSE: RDY) reported the completion of the acquisition of GlaxoSmithKline’s (GSK) United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010 (Press release, Dr Reddy’s, MAR 30, 2011, View Source [SID1234571043]). As a result of the acquisition, Dr. Reddy’s assumes the ownership of the penicillin manufacturing site in Bristol, Tennessee, United States, and rights for the Augmentin and Amoxil brands in the United States. GSK will retain the existing rights for these brands outside the United States. Further financial terms and conditions of the transaction are not being disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!